OpenAlex
PricingAboutJobs
Log inGet started
Work

Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study

HTML

Year: 2018
Type: conference-abstract
Source: Cancer Research
DOI: 10.1158/1538-7445.sabcs17-pd3-11
Authors: C Jackisch, D Stroyakovskiy, X Pivot, J-S Ahn, B Melichar, S-C Chen, C Meyenberg, N Al-Sakaff, D Heinzmann, R Hegg
Institutions: F. Hoffmann-La Roche AG, Samsung Medical Center, Chang Gung Memorial Hospital, Centre Hospitalier Universitaire de Besançon, Linkou Chang Gung Memorial Hospital, Sana Klinikum Offenbach, Moscow City Oncology Hospital №62, Palacký University Olomouc, Sungkyunkwan University
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: trastuzumab, HER2-positive breast cancer, subcutaneous trastuzumab, neoadjuvant therapy, adjuvant therapy, event-free survival, overall survival, pathological complete response, long-term follow-up, adverse events, HER2-targeted therapy, docetaxel, FEC chemotherapy, Hannah
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2793042150
Cites:
Cited by: 3
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security